Berberine vs Inositol
Two metabolic supplements that overlap heavily in the PCOS/insulin-resistance conversation — one with a wider glucose/lipid trial base, the other with the more PCOS-specific evidence.
Berberine
Real (low-certainty) human evidence for glucose and lipids; the 'nature's Ozempic' weight-loss claim is not supported.
Full Berberine evidence reviewInositol
Myo-inositol, D-chiro-inositol
Improves menstrual-cycle regularity in pooled PCOS trials, but the 2023 international guideline graded the evidence very low certainty — live birth is unproven and the 40:1 ratio is unvalidated in humans.
Full Inositol evidence reviewSide by side
| Berberine | Inositol | |
|---|---|---|
| Marketed for | Blood sugar, lipids, 'nature's Ozempic' | PCOS, insulin sensitivity, fertility, anxiety |
| Evidence grade | Clinical data | Clinical data |
| Family | Metabolic / AMPK | Metabolic / AMPK |
| Key human source | Meta-analysis, J Ethnopharmacol 2015 | Guideline systematic review, JCEM 2024 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Berberine's trial base is broader (glucose, lipids, general metabolic markers) but low-certainty overall, and its 'nature's Ozempic' weight-loss framing isn't supported. Inositol's evidence is more specifically PCOS-focused — pooled trials show it improves menstrual-cycle regularity — but a 2023 international guideline graded even that evidence very low certainty, and the popular 40:1 myo-to-D-chiro ratio has never itself been validated in a head-to-head human trial.
Berberine fits if
General metabolic/glucose support is the goal, not specifically PCOS.
Inositol fits if
PCOS or fertility-adjacent insulin resistance is the specific target, understanding the evidence grade is still low.